Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05291286 · ClinicalTrials.gov registry record · Early Phase 1

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

A Early Phase 1 study of Chemotherapy-induced Peripheral Neuropathy and Neuropathy;Peripheral, sponsored by Bexion Pharmaceuticals.

Completed
Registry status
Early Phase 1
Development phase
21
Enrollment target
3
Study locations

NCT05291286: Completed Early Phase 1 study of Chemotherapy-induced Peripheral Neuropathy and Neuropathy;Peripheral, sponsored by Bexion Pharmaceuticals.

NCT05291286 is a Early Phase 1 study of Chemotherapy-induced Peripheral Neuropathy and Neuropathy;Peripheral that has completed, run by Bexion Pharmaceuticals. The registered enrollment target is 21 participants, below the 138-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05291286, a Early Phase 1 study of Chemotherapy-induced Peripheral Neuropathy and Neuropathy;Peripheral, has completed, sponsored by Bexion Pharmaceuticals.

COMPLETED
Registry status
Early Phase 1
Development phase
21 participants
Enrollment target
3
Study locations

Study Summary

This study will assess pharmacokinetic (PK)/pharmacodynamic (PD) relationships and whether BXQ-350 may decrease the intensity and/or duration of chemotherapy induced peripheral neuropathy (CIPN) thereby improving quality of life (QoL) in cancer patients who have been exposed to oxaliplatin and/or taxane-based chemotherapy. This study includes two randomized, placebo controlled, blinded treatment cycles of BXQ-350/placebo, an optional open-label BXQ-350 treatment period, and an unblinded Post-Treatment Follow-up period.

Primary Outcome

To evaluate the Cmax of BXQ-350.

Conditions Studied

Chemotherapy-induced Peripheral Neuropathy Neuropathy;Peripheral

Interventions

  • OTHER Placebo
  • DRUG BXQ-350

Study Locations (3)

Ohio

  • CTI Clinical Research Center - Cincinnati
  • The Ohio State Unviersity - Columbus

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2022-10-17
Est. Completion 2024-12-20
Phase Early Phase 1
Bexion Pharmaceuticals

6 total trials

What the finished NCT05291286 record still lists

NCT05291286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 138-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05291286 reports a single indexed study location in Ohio, Tennessee.

Frequently Asked Questions

What is clinical trial NCT05291286 about?

NCT05291286 is a clinical study titled "BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients". This study will assess pharmacokinetic (PK)/pharmacodynamic (PD) relationships and whether BXQ-350 may decrease the intensity and/or duration of chemotherapy induced peripheral neuropathy (CIPN) thereby improving quality of life (QoL) in cancer patients who have been exposed to oxaliplatin and/or ta...

What is the current status of trial NCT05291286?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2022-10-17. Estimated completion is 2024-12-20.

What conditions does trial NCT05291286 study?

This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy, Neuropathy;Peripheral.

What interventions are being tested in trial NCT05291286?

The interventions under investigation include: Placebo (OTHER), BXQ-350 (DRUG).

Who is sponsoring clinical trial NCT05291286?

This trial is sponsored by Bexion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05291286 being conducted?

This trial has 3 study locations across Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chemotherapy-induced Peripheral Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05291286's enrollment target sits among peer trials

21 22nd of 29 higher than 8 of 29 other Chemotherapy-induced Peripheral Neuropathy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chemotherapy-induced Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05291286, the US trial registry maintained by the National Library of Medicine. NCT05291286 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.